The US has approved the world’s first chikungunya vaccine, Ixchiq, developed by Valneva, addressing a global health threat
In a landmark decision, US health authorities granted approval on Thursday for the world’s inaugural vaccine against chikungunya, a mosquito-borne virus labeled by the Food and Drug Administration (FDA) as an “emerging global health threat.”
The green signal comes as a crucial step in combating the virus’s spread, especially in regions where it is most prevalent.
Developed by Europe’s Valneva, the vaccine, named Ixchiq, has been authorized for individuals aged 18 and over who face an elevated risk of exposure, as per the FDA’s announcement.
